A Phase 3 interventional study of Brivaracetam in Epilepsy, sponsored by UCB PHARMA Inc. (US). Completed at 100 sites in 6 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-08-17.
Sponsored by UCB PHARMA Inc. (US) (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 4th largest by enrollment, is the only one that started in 2006, is one of 21 in phase 3, and was the 1st registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2006.
This study's enrollment of 668 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB PHARMA Inc. (US), one of the names counted as UCB S.A.. Under that name alone:
This is the only study on the registry with UCB PHARMA Inc. (US) as lead sponsor.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 7th largest by enrollment of the 116 interventional ones that give a count, is one of 7 that started in 2006, is one of 74 in phase 3, and was the 3rd registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label brivaracetam treatment.
Study access was limited to subjects having completed one of the previous brivaracetam (BRV) studies: N01193 [NCT00175825], N01252 [NCT00490035], N01253 [NCT00464269], N01254 [NCT00504881].
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brivaracetam used as adjunctive treatment, flexible dosing up to 200 mg /day in b.i.d (twice daily) administration. Dose increase or decrease can be made in increments of maximum 50 mg/day on a weekly basis.
Drug: Brivaracetam
* Active Substance: Brivaracetam * Pharmaceutical Form: Tablet * Concentration: 10 mg and 25 mg * Route of Administration: Oral
Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) During the Study Period
Treatment-Emergent Adverse Events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.
Time frame: Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)
Percentage of Participants Who Withdrew Due to an Adverse Event (AE) During the Study Period
Adverse Events (AE) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.
Time frame: Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)
Percentage of Participants With a Serious Adverse Event (SAE) During the Study Period
A Serious Adverse Event (SAE) is any untoward medical incidence that occurs at any dose.
Time frame: Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)
Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation Period
Baseline is the Baseline from subject's previous study of enrollment period. N01193 \[NCT00175825\], N01252 \[NCT00490035\], N01253 \[NCT00464269\], N01254 \[NCT00504881\]. A 28 day Type 1 seizure frequency is the total number of Type 1 seizures divided by the total number of days evaluated multiplied by 28.
Time frame: From Baseline of the previous study to the Evaluation Period (up to 11 years)
Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period
The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as: (the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines.
Time frame: From Baseline of the previous study to the Evaluation Period (up to 11 years)
Percentage of Participants With Response for Partial Onset Seizure (POS) (Type I) Frequency Over the Evaluation Period
A responder is defined as a subject with a higher than or equal to (\>=) 50 % change in seizure frequency from Baseline period of the previous study.
Time frame: From Baseline of the previous study to the Evaluation Period (up to 11 years)
The study started to enroll patients in January 2006 and concluded in September 2017. 668 subjects were included in the Enrolled Set but 1 subject from India lost to follow up and was excluded from the Safety Analysis Set due to lack of medical data.
| Milestone | Brivaracetam |
|---|---|
| Started | 667 |
| Completed | 171 |
| Not completed | 496 |
| Withdrew: Adverse event | 89 |
| Withdrew: Death | 18 |
| Withdrew: Lack of efficacy | 166 |
| Withdrew: Lost to follow-up | 58 |
| Withdrew: Subject's choice | 90 |
| Withdrew: No compliance | 18 |
| Withdrew: Ip misshandling | 1 |
| Withdrew: Site closure | 24 |
| Withdrew: Protocol non-adherence | 2 |
| Withdrew: Nobody to accompany patient | 1 |
| Withdrew: Distance too long for patient | 1 |
| Withdrew: Neurosurgery | 2 |
| Withdrew: Brv monotherapy | 1 |
| Withdrew: Visit refusal | 3 |
| Withdrew: Sponsor's request | 2 |
| Withdrew: Generalized epilepsy | 1 |
| Withdrew: Moved from area/country | 8 |
| Withdrew: Pi retiring | 2 |
| Withdrew: Pi leaving site | 2 |
| Withdrew: Patient insurance | 1 |
| Withdrew: Surgical intervention | 4 |
| Withdrew: Pregnancy planned | 1 |
| Withdrew: Pi discontinuation request | 1 |
Treatment-Emergent Adverse Events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.
| percentage of participants | Brivaracetam (SS) |
|---|---|
| Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) During the Study Period | 91.2 |
Adverse Events (AE) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.
| percentage of participants | Brivaracetam (SS) |
|---|---|
| Percentage of Participants Who Withdrew Due to an Adverse Event (AE) During the Study Period | 14.8 |
A Serious Adverse Event (SAE) is any untoward medical incidence that occurs at any dose.
| percentage of participants | Brivaracetam (SS) |
|---|---|
| Percentage of Participants With a Serious Adverse Event (SAE) During the Study Period | 22.8 |
Baseline is the Baseline from subject's previous study of enrollment period. N01193 \[NCT00175825\], N01252 \[NCT00490035\], N01253 \[NCT00464269\], N01254 \[NCT00504881\]. A 28 day Type 1 seizure frequency is the total number of Type 1 seizures divided by the total number of days evaluated multiplied by 28.
| Seizures per 28 days | Brivaracetam (POS-ES) |
|---|---|
| baseline | 9.2 (5.5 to 20.2) |
| on treatment | 4.2 (1.6 to 11.3) |
The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as: (the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines.
| percent change | Brivaracetam (POS-ES) |
|---|---|
| Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period | 57.3 (18.6 to 82.2) |
A responder is defined as a subject with a higher than or equal to (\>=) 50 % change in seizure frequency from Baseline period of the previous study.
| percentage of participants | Brivaracetam (POS-ES) |
|---|---|
| Percentage of Participants With Response for Partial Onset Seizure (POS) (Type I) Frequency Over the Evaluation Period | 55.6 |
Collected over Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brivaracetam | 18/667 (2.7%) | 152/667 (22.8%) | 521/667 (78.1%) |
| Event | Brivaracetam |
|---|---|
| ConvulsionNervous system disorders | 15/667 |
| PneumoniaInfections and infestations | 7/667 |
| Suicide attemptPsychiatric disorders | 7/667 |
| Status epilepticusNervous system disorders | 6/667 |
| PregnancyPregnancy, puerperium and perinatal conditions | 5/667 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 4/667 |
| Transient ischaemic attackNervous system disorders | 4/667 |
| Myocardial infarctionCardiac disorders | 3/667 |
| Unevaluable eventGeneral disorders | 3/667 |
| Urinary tract infectionInfections and infestations | 3/667 |
| Event | Brivaracetam |
|---|---|
| HeadacheNervous system disorders | 165/667 |
| DizzinessNervous system disorders | 142/667 |
| NasopharyngitisInfections and infestations | 94/667 |
| SomnolenceNervous system disorders | 91/667 |
| InfluenzaInfections and infestations | 84/667 |
| Upper respiratory tract infectionInfections and infestations | 76/667 |
| ConvulsionNervous system disorders | 70/667 |
| DepressionPsychiatric disorders | 70/667 |
| PyrexiaGeneral disorders | 69/667 |
| NauseaGastrointestinal disorders | 67/667 |
The Baseline Characteristics refers to the Safety Analysis Set which included all subjects who took at least 1 dose of study drug.
| Age, Categorical(Participants) | Brivaracetam |
|---|---|
| <=18 years | 30 |
| Between 18 and 65 years | 632 |
| >=65 years | 5 |
| Age, Continuous(years) | Brivaracetam |
|---|---|
| Mean | 34.3 ± 12.2 |
| Sex: Female, Male(Participants) | Brivaracetam |
|---|---|
| Female | 303 |
| Male | 364 |
| Race/Ethnicity, Customized(Participants) | Brivaracetam |
|---|---|
| American Indian/Alaskan Native | 21 |
| Asian | 206 |
| Black | 18 |
| Native Hawaiian Or Other Pacific Islander | 1 |
| White | 361 |
| Other/Mixed | 60 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jan 2006, a primary completion of Sep 2017 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2018, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam